This site is intended for healthcare professionals

After data from phase III ACIS study, Erleada + Zytiga combination will not be pursued for prostate cancer.- Janssen Pharma

Read time: 1 mins
Last updated:28th Jun 2021
Published:21st Apr 2021
Condition: Prostate Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest